TIE-2/VEGFR-2 kinase-IN-1 is used for the synthesis of TIE-2 and/or VEGFR-2 inhibitors, extracted from patent WO2003022852, example 14. TIE-2/VEGFR-2 kinase-IN-1 is used for the study of diseases associated with inappropriate angiogenesis[1].
Angiopoieten 1 is a ligand for the endotheiium-specific receptor tyrosine kinase, TIE-2 is a novel angiogenic factor[1].Inhibition of TIE-2 is expected to serve to disrupt remodeling and maturation of new vasculature initiated by angiogenesis thereby disrupting the angiogenic process. Inhibition at the kinase domain binding site of VEGFR-2 would block phosphorylation of tyrosine residues and serve to disrupt initiation of angiogenesis.
[1]. Jerry Leroy Adams, et al. Furo-and thienopyrimidine derivatives as angiogenesis inhibitors. Patent WO2003022852.